10x Genomics, Inc.
NASDAQ:TXGMedical - Healthcare Information Services
+$2.49 today
- Market cap
- $6.93B
- Beta
- 2.11
- P/E (TTM)
- -196.0
- EPS (TTM)
- -$0.18
Volume 2.10M
Average 3.06M
TXG Account Payables
Amounts the company owes suppliers for goods and services received.
10x Genomics, Inc.NASDAQ: TXG
Account Payables · Q3 FY2026 · quarter ended Sep 2026
Account payables rises 19.5% from a year ago
Account payables stood at $21.59M at the end of Q3 FY2026, up 19.5% from a year earlier and up 4.3% from the prior quarter. Over 3 fiscal years it compounded at -16.2% a year.
Context
- Account payables amounted to 2.0% of total assets at the end of Q3 FY2026, up 0.3 pp from a year earlier.
- Account payables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +19.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 12.73M USD
- Year-over-year change
- -1.4%
- 4-year CAGR
- -7.4%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.73M | -1.4% |
| FY2024 | 2024-12-31 | 12.91M | -18.0% |
| FY2023 | 2023-12-31 | 15.74M | -27.1% |
| FY2022 | 2022-12-31 | 21.6M | +24.5% |
| FY2021 | 2021-12-31 | 17.35M | — |
Account Payables vs competitors
How TXG compares with its peers on the latest reported figures
- TXG's Sep 2026 account payables of $21.59M is the 8th highest of the 9 companies compared; the peer median is $111.29M.
- Its year-over-year change of +19.5% is the 2nd highest of 9, against a peer median of +2.9%.
- Account payables amounts to 2.0% of total assets for TXG, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $608M | +14.7% | -0.6% | 4.4% | |
| Jun 2026 | $230M | +15.0% | -6.4% | 3.5% | |
| Jul 2026 | $165.74M | -7.0% | -12.1% | 1.4% | |
| Jun 2026 | $143.5M | +3.0% | -1.5% | 1.4% | |
| Jun 2026 | $79.08M | -4.0% | -9.7% | 1.3% | |
| Sep 2026 | $31M | +2.8% | +1.3% | 1.2% | |
| Sep 2026 | $24.85M | +124.0% | +20.9% | 2.2% | |
| Sep 2026 | $21.59M | +19.5% | -16.2% | 2.0% | |
| Mar 2026 | $8.01M | -32.0% | -11.9% | 1.3% | |
| Peer median (excluding TXG) | $111.29M | +2.9% | -4.0% | 1.4% | |
Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 587.45M | 219.75M | 359.28M | 344.07M | 473.97M |
| Short-term Investments | 0 | 210.24M | 29.41M | 49.34M | 49.44M |
| Net Receivables | 85.25M | 104.21M | 114.83M | 87.86M | 82.49M |
| Inventory | 59.97M | 81.63M | 73.71M | 83.11M | 56.34M |
| Other Current Assets | 1.03M | 19.21M | 18.79M | 20.02M | 22.21M |
| Total Current Assets | 747.59M | 635.04M | 596.02M | 584.39M | 684.45M |
| Property, Plant & Equipment (Net) | 230.41M | 359.21M | 344.93M | 309.94M | 287.16M |
| Goodwill | 4.51M | 4.51M | 4.51M | 4.51M | 4.51M |
| Intangible Assets | 25.4M | 22.86M | 16.62M | 15.67M | 62.33M |
| Long-term Investments | 7.6M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.32M | 7.37M | 3.06M | 4.13M | 2.91M |
| Total Non-current Assets | 271.24M | 393.95M | 369.12M | 334.25M | 356.91M |
| Total Assets | 1.02B | 1.03B | 965.14M | 918.64M | 1.04B |
| Account Payables | 17.35M | 21.6M | 15.74M | 12.91M | 12.73M |
| Short-term Debt | 0 | 0 | 0 | 0 | 10.99M |
| Tax Payables | 4.62M | 4.08M | 5.05M | 4.94M | 0 |
| Deferred Revenue | 5.34M | 7.87M | 13.15M | 20.66M | 23.9M |
| Other Current Liabilities | 40.91M | 29.74M | 33.96M | 41.84M | 63.33M |
| Total Current Liabilities | 110.36M | 130.96M | 127.16M | 117.63M | 153.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 73.38M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 3.17M | 8.81M | 12.51M | 10.5M |
| Other Non-current Liabilities | 14.05M | 2.98M | 4.28M | 5.03M | (65.67M) |
| Total Non-current Liabilities | 90.9M | 92.28M | 96.94M | 90.87M | 91.59M |
| Total Liabilities | 201.26M | 223.24M | 224.1M | 208.5M | 245.04M |
| Common Stock | 2K | 2K | 2K | 2K | 2K |
| Retained Earnings | (863.32M) | (1.03B) | (1.28B) | (1.47B) | (1.51B) |
| Accumulated OCI | 22K | (4.34M) | (429K) | (493K) | 225K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 817.57M | 805.74M | 741.04M | 710.13M | 796.33M |
| Total Debt | 81.98M | 95.18M | 95.37M | 82.61M | 157.74M |
| Net Debt | (505.47M) | (124.57M) | (263.91M) | (261.45M) | (316.23M) |
10x Genomics, Inc.
NASDAQ:TXG
Intrinsic Alpha fair value
Locked
Current Price
$57.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.